These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Targeted Therapy of Atherosclerosis by a Broad-Spectrum Reactive Oxygen Species Scavenging Nanoparticle with Intrinsic Anti-inflammatory Activity. Wang Y; Li L; Zhao W; Dou Y; An H; Tao H; Xu X; Jia Y; Lu S; Zhang J; Hu H ACS Nano; 2018 Sep; 12(9):8943-8960. PubMed ID: 30114351 [TBL] [Abstract][Full Text] [Related]
9. C-Reactive Protein Binds to Cholesterol Crystals and Co-Localizes with the Terminal Complement Complex in Human Atherosclerotic Plaques. Pilely K; Fumagalli S; Rosbjerg A; Genster N; Skjoedt MO; Perego C; Ferrante AMR; De Simoni MG; Garred P Front Immunol; 2017; 8():1040. PubMed ID: 28900428 [TBL] [Abstract][Full Text] [Related]
10. Macrophage Membrane-Encapsulated Dopamine-Modified Poly Cyclodextrin Multifunctional Biomimetic Nanoparticles for Atherosclerosis Therapy. Zhu L; Zhong Y; Yan M; Ni S; Zhao X; Wu S; Wang G; Zhang K; Chi Q; Qin X; Li C; Huang X; Wu W ACS Appl Mater Interfaces; 2024 Jun; 16(25):32027-32044. PubMed ID: 38867426 [TBL] [Abstract][Full Text] [Related]
12. Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages. Donat C; Thanei S; Trendelenburg M Front Immunol; 2019; 10():2712. PubMed ID: 31824501 [TBL] [Abstract][Full Text] [Related]
13. Cyclodextrins: Potential therapeutics against atherosclerosis. Mahjoubin-Tehran M; Kovanen PT; Xu S; Jamialahmadi T; Sahebkar A Pharmacol Ther; 2020 Oct; 214():107620. PubMed ID: 32599008 [TBL] [Abstract][Full Text] [Related]
14. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis. Dou Y; Chen Y; Zhang X; Xu X; Chen Y; Guo J; Zhang D; Wang R; Li X; Zhang J Biomaterials; 2017 Oct; 143():93-108. PubMed ID: 28778000 [TBL] [Abstract][Full Text] [Related]
15. Preclinical Reversal of Atherosclerosis by FDA-Approved Compound that Transforms Cholesterol into an Anti-Inflammatory "Prodrug". Mendelsohn AR; Larrick JW Rejuvenation Res; 2016 Jun; 19(3):252-5. PubMed ID: 27241174 [TBL] [Abstract][Full Text] [Related]
16. Cyclodextrin-mediated conjugation of macrophage and liposomes for treatment of atherosclerosis. Gao C; Liu C; Chen Q; Wang Y; Kwong CHT; Wang Q; Xie B; Lee SMY; Wang R J Control Release; 2022 Sep; 349():2-15. PubMed ID: 35779655 [TBL] [Abstract][Full Text] [Related]
17. Cholesterol crystal formation is a unifying pathogenic mechanism in the development of diabetic retinopathy. Hammer SS; Dorweiler TF; McFarland D; Adu-Agyeiwaah Y; Mast N; El-Darzi N; Fortmann SD; Nooti S; Agrawal DK; Pikuleva IA; Abela GS; Grant MB; Busik JV Diabetologia; 2023 Sep; 66(9):1705-1718. PubMed ID: 37311879 [TBL] [Abstract][Full Text] [Related]
18. Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity. Kim H; Han J; Park JH J Control Release; 2020 Mar; 319():77-86. PubMed ID: 31843641 [TBL] [Abstract][Full Text] [Related]
19. Viewing atherosclerosis through a crystal lens: How the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability. Nidorf SM; Fiolet A; Abela GS J Clin Lipidol; 2020; 14(5):619-630. PubMed ID: 32792218 [TBL] [Abstract][Full Text] [Related]
20. Macrophage Membrane Spontaneously Encapsulated Cyclodextrin-Based Nanomedicines for Improving Lipid Metabolism and Inflammation in Atherosclerosis. Mou N; Duan X; Qu K; Chen Q; He Z; Cao Y; Zhang K; Qin X; Zhu L; Han Z; Li C; Zhong Y; Wu W ACS Appl Mater Interfaces; 2024 Sep; 16(37):49660-49672. PubMed ID: 39240784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]